Researcher

Congbao Kang obtained his PhD from Nanyang Technological University, Singapore where he was awarded the prestigious Singapore Millennium Foundation (SMF) PhD scholarship. Following his postdoctoral study at Medical School of Vanderbilt University, he received the A*STAR Investigatorship award and joined A*STAR as a Group Leader in 2009. He utilises solution NMR spectroscopy to uncover the structures and dynamics of membrane proteins, including ion channels and receptors, as well as proteins from viruses such as Dengue, Zika, and SARS-CoV-2. His team also conducts fragment screening and explores macromolecule-ligand interactions to drive forward drug discovery efforts. He co-founded Ligature Therapeutics to develop novel protein degraders. Presently, he leads the structural biology team at EDDC, focusing on understanding the mechanisms of action of diverse drug modalities through the application of structural and biophysical techniques such as NMR, X-ray and Cryo-EM with aims to facilitate target-based drug design for developing innovative pharmaceuticals.